Ascendis Pharma A/S (NASDAQ:ASND) Given New $274.00 Price Target at Canaccord Genuity Group

Ascendis Pharma A/S (NASDAQ:ASND) had its target price raised by Canaccord Genuity Group from $268.00 to $274.00 in a research report report published on Friday,Benzinga reports. Canaccord Genuity Group currently has a hold rating on the biotechnology company’s stock.

A number of other research analysts also recently commented on ASND. Jefferies Financial Group dropped their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Cantor Fitzgerald boosted their target price on Ascendis Pharma A/S from $300.00 to $315.00 and gave the company an “overweight” rating in a report on Friday. Oppenheimer upped their target price on Ascendis Pharma A/S from $304.00 to $312.00 and gave the company an “outperform” rating in a research report on Tuesday, September 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, October 13th. Finally, UBS Group assumed coverage on Ascendis Pharma A/S in a research note on Thursday, October 15th. They set a “buy” rating and a $269.00 price target on the stock. Nineteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $313.52.

Ascendis Pharma A/S Stock Up 3.1%

Shares of Ascendis Pharma A/S stock opened at $275.39 on Friday. Ascendis Pharma A/S has a 52-week low of $188.08 and a 52-week high of $282.15. The company has a 50 day moving average of $242.67 and a 200 day moving average of $239.83. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $17.18 billion, a P/E ratio of 18.00 and a beta of 0.40.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 44.80% and a net margin of 73.26%. As a group, research analysts forecast that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares in the company, valued at $810,570. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 40.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ASND. Perceptive Advisors LLC increased its stake in Ascendis Pharma A/S by 41.6% in the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares during the period. Sei Investments Co. raised its holdings in shares of Ascendis Pharma A/S by 24.8% in the first quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock valued at $80,318,000 after buying an additional 69,673 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Ascendis Pharma A/S by 27.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 227,013 shares of the biotechnology company’s stock valued at $51,602,000 after buying an additional 48,275 shares during the last quarter. Frazier Life Sciences Management L.P. raised its holdings in shares of Ascendis Pharma A/S by 68.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock valued at $60,053,000 after buying an additional 91,822 shares during the last quarter. Finally, Empowered Funds LLC boosted its stake in shares of Ascendis Pharma A/S by 0.5% during the third quarter. Empowered Funds LLC now owns 188,229 shares of the biotechnology company’s stock worth $42,884,000 after buying an additional 958 shares during the period.

Latest Ascendis Pharma A/S News

Investors following ASND have been watching these news items:

• Positive Sentiment: Q3 results and commercial growth were strong. Ascendis reported revenue of $418.7 million, above analyst expectations, while product revenue reached €366 million, up 89% year over year. YORVIPATH accounted for €291 million of product sales. The company also reported a quarterly profit, marking a shift toward commercial-scale profitability. Ascendis Pharma Q3 2026 results
• Positive Sentiment: Analyst updates lean bullish. TD Cowen raised its target to $352 and UBS lifted its target to $315, both maintaining buy ratings. Cantor Fitzgerald also raised its target to $315 with an overweight rating; RBC reaffirmed outperform at $290. These higher targets indicate continued analyst confidence in the outlook. Read More. · Read More. · Read More. · Read More.
• Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.